Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q3 2016

RGLS Guru Trades in Q3 2016

Jim Simons 645,000 sh (New)
» More
Q4 2016

RGLS Guru Trades in Q4 2016

Paul Tudor Jones 46,688 sh (New)
Jim Simons 321,200 sh (-50.20%)
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:NWBO, OTCPK:AAVXF, NAS:DRNA, OTCPK:THCBF, OTCPK:COTQF, AMEX:NBY, AMEX:RNN, OTCPK:AMEUF, NAS:AVEO, OTCPK:MTFBF, NAS:TCON, NAS:ADMA, NAS:ALDX, OTCPK:IGXT, OTCPK:TBQBF, NAS:CAPR, OTCPK:CWBR, NAS:BCLI, NAS:BUR, NAS:PULM » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing drugs that target micro RNAs to treat various diseases.

Regulus Therapeutics Inc was originally formed as a Delaware limited liability company under the name Regulus Therapeutics LLC on September 6, 2007. In January 2009, it converted Regulus Therapeutics LLC to a Delaware corporation and changed its name to Regulus Therapeutics Inc. The Company is a biopharmaceutical company engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases. microRNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. The Company has established Regulus microMarkers, a division engaged in identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Through its microRNA target identification and validation efforts it has developed proprietary technologies for microRNA profiling and analysis of human clinical samples such as tissue. The Company has licensed patent rights from Julius-Maximilians-Universität Würzburg and Bayerische Patent Allianz GmBH, which rights encompass the use of anti-miR therapeutics targeting miR-21 for the treatment of fibrosis, including kidney, liver, lung and cardiac fibrosis. It has also license from Stanford University, or Stanford, to patent rights concerning the use of anti-miR therapeutics targeting miR-122 for the treatment of HCV infection. It has also licensed from ETH Zürich to patent rights related to the use of anti-miR therapeutics targeting miR-103/107 for the treatment of metabolic disorders, including type 2 diabetes. The Company's portfolio of exclusively and jointly owned patent and patent applications is currently composed of over 150 U.S. and foreign patents and patent applications with claims to compositions-of-matter or methods related to its microRNA drug products and microRNA product platform. The Company faces competition from other biotechnology and pharmaceutical companies. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those the Company is developing.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $12.04
EPS (TTM) $ -1.30
Beta2.55
Short Percentage of Float8.50%
52-Week Range $1.05 - 8.90
Shares Outstanding (Mil)52.92

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 1 3
EPS ($) -1.56 -1.40 -1.53 -1.75
EPS w/o NRI ($) -1.56 -1.40 -1.53 -1.75
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
Top Insider Buys, Sells of the Week Feb 26 2016 
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Feb 21 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf... Feb 21 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Feb 21 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Feb 21 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Feb 17 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Feb 17 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Feb 17 2017
Lifshitz & Miller LLP Announces Investigation of Aetna Inc., GenVec, Inc., Ixia, McKesson... Feb 17 2017
Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target... Feb 16 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Feb 15 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Feb 15 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Feb 14 2017
Robbins Arroyo LLP: Regulus Therapeutics Inc. (RGLS) Misled Shareholders According to a Recently... Feb 14 2017
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Feb 14 2017
EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Files in U.S. District Court to Recover Losses Suffered... Feb 14 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Feb 13 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Feb 10 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Feb 10 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Regulus Therapeutics Inc. of a Class... Feb 10 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Feb 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)